CLINICAL GASTROENTEROLOGY

Clinical experience with 1, pivalate

STEPHEN B. HANAUER. MD

ease. In the United States, 100 m~ ABSTRACT: Tixocorcol pivalate, the 21-thiol derivative of . is a hyd rocortisone rctcn tion enemas newly synthesized with topical anti-inflammatory properties but is devoid of (Corccnema, Reid-Rowell) have become systemic and mineralocorticoid activities and toxicity. The mechanism the most widely prescribed local ther· of actic.•. appears to be similar to that of other with regard to steroid binding sites and prostaglandin biosynthesis, however. the disassociation between apy for distal colitis. However. contmu· local and systemic effects is due to a 'first pass' liver metabolism and rapid transfor­ ous therapy with topical hydroconi,one mation with in red blood cells. ln both open and controlled studies in patients with is complicated by the conscquenct's ot acute or recurrent distal colitis, clinical efficacy has been noted at doses of 2 50 mg to significant systemic absorption propor· LOOO mg in 100 ml solution without an effect on scrum levels or blood tional to the administered dose and chro­ chemistries. Tixocortol pivalace has consistently shown to be as effective as systemi­ nicity of treatmen t (7-9). cally absorbed for the treatment of distal ulcerative colitis with out the unde­ Tixocor to! pivalate ( pregn-4-cne· sirable effects associated with currently available steroid preparations. Can J Gas­ 3.20-dione-2l-thiol- llb. 17 dihydroxy· troc nte rol 1988;2( 4 ): 156-8 21-pivalatc), the 21-thiol derivative of Key Words: Anri-in/lammaiory, Sreroid, Ulcerative colitis hydrocorcisone (Figure I ), 1s a newly syn· thcsizcd steroid with anti-inflammatory

LCERATIVE COLITIS REMAINS A DIS· Shortly after the introduction of oral U order of unknown etiology ( l). Des­ as therapy for ulcerative coli­ ~"· pite potentially li fe threatening tis. Truelove (3, 4) described the use of CH,- a - co-C:-CH I I ' pancolonic and transmural inflamma­ topical hydrocortisone by rectal drip. tion, the inflammatory response is lim­ Sub sequent randomized, controll ed ~--·· '"· ited to the mucosa of the rectum and sig­ trials by Truelove (5) and Watkinson (6) moid in the majority of cases (2). The confirmed the effectiveness of 100 mg superfi cial nature and limited extent of intrarectal doses of hydrocortisonc 0 the inflammauon often make ulcerative hemisuccinate solutions compared to pla­ CH,OH colitis amenable to local (intrarectal} cebo in achieving clinical, sigmoidoscopic I treatment and histologic improvement of active dis- CH C•O . - OH

Dcpanmen1 uj McJicmc, Uniwrnry of Clucago Medical Cencer, Chicago. //lmoi .1 .,.,; Corrc.1/m11Jcncc and rc/mnt1 Dr Scephcn B Hanaitl'T, Assis1an1 Profe.15or of Medicine, Secuon of 0 Gastrocnrerolugy, Un1wr111y of Ch1wgo, 1841 Sowh Maryland Avenue, Chicago, JL 60637, USA Thi, paper u-as J1rcsenwcl m Falk Sympomcm No 49 'Trends m mjlammawry bowel diseme Figure I) Molecular .11rnc111rc.111/ 1ix11cor1ol 1herafry hdJ ,11 Luke Loimc, Alherra , Apn/ 2().23. 1988 J11wlaw I wp! anJ hyJrocorn1one

156 CAN J GASTROENHROL Clinica l experience with tixocortol plvolote

properties in animal models of inflam­ not receiving oral or local steroids, related side effects were observed in the mation (Sandoz Pharmaceuticals, data alth ough continued therapy with tixocorrol treated patients. T he only con­ on file). Moreover, it has the unique fea­ sulfasalazine was allowed and analyzed sistently significant laboratory parame­ tu re of topical an ti-inflammatory effects separately ( 13, 14). The trials all lasted ters found to be altered were the white without the typical hormonal and met­ for three weeks with weekly evaluations blood count which was increased abolic effects of systemic ab orption ( ll). of symptoms and signs of ulcerative coli­ (increased neutrophils, decreased lym­ Hence, tixocortol pivalatc is considered tis, hematologic and clinical chemistry phocytes and eosinophils) and the scrum the first of a new class, the 'nonsystemic' parameters, as well as determinations of potassium which was decreased in the steroids. 08:00 seru m cortisol levels. Proctoscopic hydrocortisone treated patien ts. Serum The mechanism of action of tixocorcol examinations were performed at base­ cortisol determinations, when measured, p1valate appears co be similar to that of line and after 14 and 22 days. were not reduced in either grou p at three other corticosteroids with regard to ste­ Symptoms of diarrhea, rectal bleed­ weeks. roid binding site~ and proscagland in b io­ ing, abdominal pain, rectal pain and gen­ Hence, after three weeks, tixocorcol synchesis. However, in both animal and eral malaise statistically improved in both pivalate was equall y effective as hydro­ human studies, ti xocortol pivalate was treatment groups, as did the number of cortisone therapy without systemic glu­ devoid of systemic glucocorticoid and bowel movements and the number of cocorticoid or mincralocorticoid effects. rnineralocorticoid activities, as well as bowel movements accompanied by Subsequently, a short term, four day toxicity, in most cases at dose levels as blood. There was a direct correlation study was performed comparing 250 mg high as 4000 mg/kg. While tixocortol with the severity of the symptoms at base­ ti xocorcol pivalate to a saline placebo pivalatc is absorbed co the same extent line and the degree of improvement; enema in 24 patients with ulcerative coli­ a,other steroids, including hydrocorti­ worse initial symptoms were associated tis or Crohn's disease of the rectum. Dur­ sone, the disassociation between local with a greater degree of improvement. ing this brief study, the symptoms of diar­ and systemic effects is due co a 'fi rst-pass' Likewise, endoscopic findings of colonic rhea. rectal b leeding a nd number of liver metabolism and rapid transforma­ hyperemia, ulceration and the physician's bowel movements, as well as procto­ rion within red blood cells ( Il, 12). overall rating of the colitis improved in scopic signs of crythcma, granu larity, both treatment groups by week 2 and mucopus and overall rating of colitis CLINICAL STUDIES contin ued to improve, such that by the improved in the tixocortol patients, Open studies: Both biological tolerance end of the th ree week study, 68% of the whereas no changes in symptoms or signs studies in patients with refractory proc­ tixocorcol pivalare and 75% of the hydro­ of inflammatory bowel disease were utis and multicen tre open studies in cortisone group had improved, and 34% observed in the placebo group (Tables I panents with acute or recu rren t distal of the tixocortol patients and 36% of the and 2). colitis have confirmed the absence of an hydrocortisone patients had healed (nei­ A randomized, double-blind, paral­ effect of tixocorcol pivalate on scrum cor­ ther proportion was statistica lly signifi­ lel group study also was conducted in usol levcls or other blood chemistries, cant between groups) (Figure 2). Patients 30 patients with ulcerative colitis to elu­ and apparent clinical efficacy using doses treated with sulfasalzine also improved cidate a dose response with higher doses of250 mg in LOO mL solutions (Sandoz in both groups. of tixocortol pivalate. Ten patients were Pharmaceuticals, data on file). Adverse reactions were typically mild, allocated to receive either 250 mg, 500 Controlled studies: Two m u lticen tre if reported. and no significant steroid mg or 1000 mg tixocortol pivalate in 100 controlled stud ies performed outside of the United States compared 250 mg tixocortol pi val ate enemas to 5 mg betame thasone phosphate with all TP HC TP HC patients receiving between l. 5 and 4 g 100 sulfasalazine. Over the three week course 90 of the studies, both enemas were well 106/141 an tolerated and equally effective in reduc­ 70 ing the symptoms of ulcerative colitis, 6 60 yet only the increased 50 50 ;.!rum cortisol (Sandoz Pharmaceuticals, 41) 40 45/133 51/ 141 daraon fi le). 30 30 In the United States, three large, con­ 20 20 trolled, double-blind, randomized, 10 10 multicentre stud ies have compared 250 0 0 mgtixocortol pivalate enemas to 100 mg PERC ENT IMPROVED hydrocortisone enemas (Cortenema; PER CENT HEALED Reid-Powell) in a total of 337 patients F igure 2) Summary of rhree US conrmllcd crials of nxocorrol pii,alate I TP J 1oers1.s hydrocornwme ( HCJ with left sided ulcerative colitis who were e11ema.1 in acute ulcerntit•e col His. Outcome after three lt'eeks

\ol 2 No. 4. November 1988 157 HANAUER

TABLE 1 TABLE 2 Physician roting o f signs on day 4 Patient roting of symptoms compared to baseline

Mucosal vascular pattern O Tixocortol pivalate Placebo Doy Doy Erythema T -< P Parameter 2 3 4 2 3 4 Granularity T -< P Diarrhea 0 0 < 0 0 0 Friability 0 Rectal bleeding 0 -< "< 0 0 0 Ulcerations O Abdominal pain 0 0 0 0 0 0 Mucopus T < P Rectal pain Summed severity Index T < P Nausea T Tixocortol pivoiote. P Plocebo Vomiting Change in appetite 0 0 0 0 0 0 ml solution over three weeks. At the Feeling of illness 0 -< < 0 0 0 conclusion of the study, no dose response Number of bowel movements 0 < -< 0 0 0 was identified in the entire group (Fig­ Number of bowel movements 0 -< -< 0 0 0 ure 3) or after analysis of the subgroups with blood of sulfasala zine treated or refractory patients. REFERENCES hemisuccinatc sodium. A controlled I. Kirsncr JB, Shorter RG Recent trial employing restricted ,cquential CONCLUSION developments in 'non-specifi c' analysis. Br Med J 1958;2: 1077-82 Tixocortol pivalate, the first of a new inflammatory howcl disease. N Engl J 7. Sherman LF, Tenner RJ. Schoulcr JL class of nonsystemic steroids devoid of Med 1982;306:775-85, 837-48. Trc::icmcnt of ulcerative colitis with glucocorticoid a nd mineralocorticoid Z. Edwards FC, Truelove SC The course hydmcorrisonc alwhol retention enemas. A topical and systemic effects, has consistently been shown to and prognosis of ulcerative colitis. Part II. Long-term prognosis. Gut anu-inflammarory agent. Part II. Di, be as effective as systemically absorbed 1963;4:309-15. Colon Rectum 1967;10:43-52. steroids for the treatment of distal ulcer­ 1. Truelove SC Treatment of ulcerative 8. Goldstei n MJ, Gelzayd EA, Kin,ner JB. ative colitis. Thus, it appears that ther­ colitis with local hydrocortisone. Some observations on the hazards of apy with ti xocortol pivalate offers the Br Medj 1956;2, 1267-72. therary in patients with inflammatory bowel disease. Trans Am advantaf.e of steroid therapy without the 4. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone Acad Ophthalmol Otolaryngol undesirable effects previously associated hemisuccinatc sodium. Br Med J [967;7 1:254-6 1. with currencly available steroid pre pa­ [957;1: 1437-43 9. Singleton JW. Medical therapy of rations. Future studies will focus on 5. Truelove SC. Treatment of ulcerative inflammatory bowel disease Med Clin longer du ration placebo controlled colitis with local hydrocorrisone North Am L980;64: lll7-33. 10. DaviesJE. Kcllct ON. Staniforth M\\', enema trials as well as the development hemisuccinate sodium. A report on a controlled th erapeutic trial. Br Med J et al Pharmacological study of a new of oral. targeted d elivery systems for the 19'58;2: 1072-7. anti-inflammatory steroid. n xocortol potential use in proximal colitis and 6. Watkin:;on G. Treatment of ulcerative pivalate (TO 1016). Arznc1mittelforsch Crohn's disease. colitis with topical hydrocortisonc 1981;3 1453-9. 11. Larochelle P, Du Sou1ch P, Colte E. ctal Tixocortol pivalate, a corticosteroid ., with no systemic glucocortoid effect after oral. intrarectal and intram1sal application. C lin Pharmacol Thcr 7'0 1983;33:341-50. 0~ ., 12. Goyer R, Lcvei lleJ, Larochelle P. et al c::: gi Preliminary report o n the fate of ,0 ti xocorrol pivalate (TP), a E-- without systemic effects. Presented ar the Wo rld conference on Clinical ti 60 15 Therapeutics. Washing· ,0 ton, DC, August 1983. "" 13 Levinson RA. lntrarectal treatment of JO ulcerative colitis with tixocorrol pivalate. a topical, nonsytcmic anti· ID inflammato ry steroid, comranson wnh hydrocortisone enema. Gastro· 0 cntcrology 1986;90: 1520. ~ ~ TPlOOO TP2:'.IO ~ TPl.000 14. Hanauer SB, Kirsncr JB. Barrctt WE. DAY H DAY 22 The treatment of left-sided ulccr;1riw colitis with ti xocortol pivah.lle (TP). F igure 3) Percentage of /wtiencs healed • and imprnt•ed D a/rer 14 days and 22 days on t•ariou.1 Gastrocnterology 1986;90: 1449 doses of 1ixocorwl /1it•alate (TP)

158 CAN j GASTROENTEROL M EDIATORSof INFLAMMATION

The Scientific Gastroenterology Journal of Research and Practice Diabetes Research Disease Markers World Journal Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 Hindawi Publishing Corporation Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014

Journal of International Journal of Immunology Research Endocrinology Hindawi Publishing Corporation Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014

Submit your manuscripts at http://www.hindawi.com

BioMed PPAR Research Research International Hindawi Publishing Corporation Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014

Journal of Obesity

Evidence-Based Journal of Stem Cells Complementary and Journal of Ophthalmology International Alternative Medicine Oncology Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014

Parkinson’s Disease

Computational and Mathematical Methods Behavioural AIDS Oxidative Medicine and in Medicine Neurology Research and Treatment Cellular Longevity Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014